The binding process is also found to lead to antigen capping and internalization of the antibody/nanotube complexes. shown to selectively bind to cancer cellsin vitroand in tumour-bearing xenografted mice. The binding process is also found to lead to antigen capping and internalization of the antibody/nanotube complexes. The nanotube conjugates were labelled with both alpha-particle and gamma-ray emitting isotopes, at high specific activities. Conjugates labelled with alpha-particle generating225Ac were found to clear rapidly, thus mitigating radioisotope toxicity, and were shown to be therapeutically effectivein vivo. Nanomedicine has begun to produce clinical successes in the first generation of engineered drug nanoparticles1,2. Carbon Amodiaquine dihydrochloride dihydrate nanotubes have seen widening application in biomedical research3, in part because of the potential to append a diverse set of ligands, including small molecules4, peptides5,6, oligonucleotides7, radioisotopes8, monoclonal antibodies9,10, and other targeting moieties. However, nanoparticle usage is limited by pharmacokinetics, and requires modifications to render them suitably water dispersible and biocompatible11,12. Functionalization and dispersion imparts stability in aqueous environments and mitigates toxicity13. An important feature of covalently-functionalized SWNTs that allows their use as drug carriers is their extremely rapid clearance via renal glomerular filtration despite large molecular weights8,14,15. This clearance phenomenon has been termed fibrillar pharmacology16and contrasts with the pharmacokinetic profiles of globular proteins. Typically, in systemic targeting of malignancies, drug delivery vehicles such as mAb or nanoparticles are appended with cytotoxic effectors such as chemotherapeutic small molecules or radioisotopes in a single-step process. However, prolonged plasma half-lives of the excess, unbound effector molecules (often exceeding 99.9% of injected species) increase toxicity. In contrast, a short circulation time for a single step delivery is problematic as it reduces the time in which a high enough concentration can be maintained in the bloodstream to drive tumour penetration and cell binding. Two-step targeting (pre-targeting) separates the slow, nontoxic tumour-targeting Amodiaquine dihydrochloride dihydrate process from the necessary rapid clearance of the cytotoxic Rabbit polyclonal to ACD agent to achieve the desired pharmacokinetic goals17. In this approach, a long-circulating tumour selective agent, such as a monoclonal antibody, is first administered and allowed a sufficient circulation time to accumulate at the tumour and clear the Amodiaquine dihydrochloride dihydrate bloodstream. This pre-targeting agent is followed by a rapidly cleared second-step agent, armed with cytotoxic or diagnostic effectors, that has a high-affinity for the initial agent. This interaction may involve streptavidin-biotin18, bispecific antibody-hapten19, oligonucleotide hybridization20, or covalent click chemistry21interactions. This approach allows for improved ratios of the cytotoxic or imaging agent in the tumour to that in the blood. Previous successes of pre-targeting have not taken advantage of particulate or nanomaterial second-step vehicles as they typically clear the body slowly and accumulate in organs such as liver and spleen22,23. Small molecules, such as biotin or an oligonucleotide, allow rapid excretion of the second-step reagent24, but are Amodiaquine dihydrochloride dihydrate usually mono-substituted, limiting potency and sensitivity25,26. SWNTs uniquely solve this problem as their structure allows for multiple appended cytotoxic moieties while still clearing rapidly10,14. We chose complementary 18-mer morpholino oligonucleotides to link SWNT vehicles and correspondingly modified monoclonal antibody pre-targeting agents as a high affinity, self-assembling linker strategy. Oligonucleotide base pairing is an attractive approach for binding of nanotubes to antibodies because oligo-modified SWNTs have been described previously27, and maintain their clearance7. If an oligo with a stabilized backbone is employed, such as with the morpholino DNA analogs20,28,29used in this study, serum degradation30,31is prevented and hybridization occursin vivo. == SWNT modification, hybridization and radiolabeling == The amine functionalized SWNTs (Figure 1, Structure1) used in the current study were prepared from high-purity, arc-discharge or HiPCO produced SWNTs via covalent cycloaddition of azomethine ylides as described previously9,14,32,33. This reaction attaches hydrophilic chains to the SWNT sidewalls, terminated with primary amines to serve as the attachment site for bifunctional radiometal chelates, fluorophores, and the morpholino oligonucleotide complementary to a modified antibody (cMORF). Using chelators appended in such a manner, we produced SWNT-cMORF-DOTA conjugates(5)that had been subsequently labeled to high specific activities, up to 25 Ci/g and 20 Ci/g when labeling with111In and225Ac, respectively. This represents a greater than 100-fold improvement in specific activity of the SWNT-cMORF compared to monoclonal antibodies10,34, and demonstrates the potential for signal amplification with highly multivalent SWNT scaffolds. == Figure 1. Design and.